Plasminogen activator

Fibrinolysis

A plasminogen activator is a serine protease which converts plasminogen to plasmin, thus promoting fibrinolysis.

Types include:

It is inhibited by plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2.

PLG

Available structures

PDB

Ortholog search: PDBe RCSB

List of PDB id codes
1B2I, 1BML, 1BUI, 1CEA, 1CEB, 1DDJ, 1HPJ, 1HPK, 1I5K, 1KI0, 1KRN, 1L4D, 1L4Z, 1PK4, 1PKR, 1PMK, 1QRZ, 1RJX, 2DOH, 2DOI, 2KNF, 2L0S, 2PK4, 3UIR, 4A5T, 4CIK, 4DCB, 4DUR, 4DUU, 5HPG

Identifiers

Aliases

PLG, Plasmin

External IDs

MGI: 97620 HomoloGene: 55452 GeneCards: PLG

Targeted by Drug

aminocaproic acid^[1]

Gene ontology
Molecular function	• apolipoprotein binding • protein domain specific binding • peptidase activity • protein binding • serine-type peptidase activity • receptor binding • serine-type endopeptidase activity • hydrolase activity
Cellular component	• blood microparticle • plasma membrane • extracellular fluid • extracellular region • cell surface • extrinsic component of external side of plasma membrane • extracellular exosome • platelet alpha granule lumen
Biological process	• hemostasis • negative regulation of cell-substrate adhesion • cellular protein metabolic process • negative regulation of fibrinolysis • fibrinolysis • negative regulation of cell-cell adhesion mediated by cadherin • platelet degranulation • extracellular matrix disassembly • proteolysis • positive regulation of fibrinolysis • tissue remodeling • negative regulation of cell proliferation • blood coagulation
Sources:Amigo / QuickGO

RNA expression pattern

More reference expression data

Orthologs

Species

Human

Mouse

Entrez


5340


18815

Ensembl


ENSG00000122194


ENSMUSG00000059481

UniProt


P00747


P20918

RefSeq (mRNA)


NM_001168338 NM_000301


NM_008877

RefSeq (protein)


NP_000292.1


NP_032903.3

Location (UCSC)

Chr 6: 160.7 – 160.75 Mb

Chr 17: 12.38 – 12.42 Mb

PubMed search

^[2]

^[3]

Wikidata

View/Edit Human

View/Edit Mouse

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban^§ Tirofiban

ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor

Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil

COX inhibitors	Acetylsalicylic acid/Aspirin^# Aloxiprin Carbasalate calcium Indobufen Triflusal

Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban^§

Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal

Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low molecular weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin^‡ Oligosaccharides Fondaparinux Idraparinux^§ Heparinoids Danaparoid Dermatan sulfate Sulodexide

Direct Xa inhibitors ("xabans")	Apixaban Betrixaban^† Darexaban^§ Edoxaban Otamixaban^§ Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 5/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.